Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 1998

View Archived Issues

Dainippon will initiate European development of antipsychotic drug candidate

Dainippon's aldose reductase inhibitor in phase II in Japan; European development now planned

Preparation and pharmaceutical formulations of nimesulide choline salt claimed by Dompe

Korean research institute develops new NMDA receptor antagonists

Agents for schizophrenia from Yoshitomi typified by Y-36074

RPR presents clinical findings with gpIIb/IIIa antagonist; product dropped due to dosing problems

Apotex conducting early studies on oral chelating agents

NeoTect effective in detecting breast cancer in early clinical study

Yamanouchi discloses 5-HT2C receptor agonists with high potency and selectivity

GeneMedicine, Megabios merger will create industry leader in gene-based therapeutics

Shiseido claims pyrrolidines for gastric and peptic ulcers

Vasogen files for protection of patient-specific treatment of GvHD

New serotonergic agents in development at ADIR for CNS disorders

ThromboSol prolongs cryopreservation of rhTPO-stimulated platelets in in vitro study

Pharmacokinetic and therapeutic equivalence of Zelapar and Eldepryl

AxyS reaches research milestones in collaboration with Warner-Lambert

No risk of liver toxicity with entacapone, Orion says

Clinical, preclinical efficacy of Neovastat featured at recent congress

Temodal recommended for approval in E.U.

Clinical testing of nonantibiotic anti-H. pylori agent will begin; development partner sought

Clinical trials of FS069 begin in Japan

New antiasthmatic agent launched in Italy by Zeneca, Chiesi and Recordati

Idec commences clinical trials with PRIMATIZED anti-B7 antibody in psoriasis

Advisory committee decides against recommending approval for new anticoagulant

New synthetic anti-HIV compound resembling NNRTIs in development at Nippon Suisan

Hughes Institute develops potent and selective d4T analogue as anti-HIV candidate

Design and synthesis of new beta-lactams as potent and selective HCMV protease inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 15, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...